Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Drug Delivery
Filter     Order     Display # 
Date Item Title Hits
31 Aug 2010 Ovatech reports successful completion of Phase 2 clinical trial of Ovaprene non-hormonal intravaginal contraceptive ring 6
30 Aug 2010 IntelGenx and RedHill Announce Definitive Agreement for Anti-Migraine Film Product 6
26 Aug 2010 Cypress Bioscience Acquires Novel Intranasal Carbetocin Therapy for Autism 6
20 Jul 2010 Edge Therapeutics and SurModics Collaborate to Develop a Drug Delivery Technology for Treatment of Secondary Brain Injury After Stroke or Traumatic Brain Injury (TBI) 24
10 May 2010 NexMed Announces Encouraging Pre-Clinical Results Showing the Ability of the NexACT Technology to Enhance the Bioavailability of rituximab When Administered Subcutaneously 1643
24 Nov 2008 Penwest Enters Into Second Research and Development Agreement With Otsuka Pharmaceutical 9179
23 Nov 2008 Covidien and Depomed Announce License Agreement 1331
13 Oct 2008 Study Finds Improved Absorption of Oral Salmon Calcitonin Versus Nasal Administration 1047
19 Aug 2008 DelSite Files IND for Nasal Powder H5N1 (Bird Flu) Influenza Vaccine 815
13 Aug 2008 Tekmira Pharmaceuticals Announces RNAi Research Collaboration with Bristol-Myers Squibb 864
05 Aug 2008 Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule 916
04 Aug 2008 Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis... 811
02 Aug 2008 MDRNA, Inc. Demonstrates In Vivo Efficacy with Proprietary DiLA2 Delivery Platform 930
27 Jul 2008 Eligen(R) B12 oral formulation demonstrates 240% improvement in bioavailability versus standard oral Vitamin B12 tablet and different absorption characteristics 1094
15 Jul 2008 BioAlliance Pharma suspends the Phase II/III trial of doxorubicin Transdrug(R) in primary liver cancer, following advice from the Drug Safety Monitoring Board and the Steering Committee 893
09 Jul 2008 Altus Pharmaceuticals Secures Long-Term Growth Hormone Supply For ALTU-238 Clinical Development and Commercialization 957
09 Jul 2008 Modigene Platform Validated in Independent Phase III Trial of CTP Technology 893
07 Jul 2008 Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations 807
29 Jun 2008 Emisphere Technologies Announces the Launch of a Human Clinical Trial For Oral Parathyroid Hormone (PTH) 909
24 Jun 2008 Promising Results for Oral CP-4126 1003
24 Jun 2008 SurModics Announces Initiation by Merck & Co., Inc. of Phase IIb Clinical Trial for I-vation(TM) TA 916
11 Jun 2008 Lilly and TransPharma Medical Announce Licensing and Development Agreement 949
30 Apr 2008 Sepracor and Arrow Sign Global License and Development Agreement Covering Technology to Enhance Ciclesonide and BROVANA(R) Franchises 1078
29 Apr 2008 Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients 998
29 Apr 2008 Phosphagenics Reports Positive Pre-clinical Results for 980
28 Apr 2008 Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon) 991
15 Apr 2008 Proof of Concept Study in Second Species Demonstrates Increase in Absorption of Oral B12 Using Emisphere Technology 1145
08 Apr 2008 Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients 982
08 Apr 2008 Pfizer Statement on Exubera Labeling Update in the United States 1007
01 Apr 2008 Pantec Biosolutions unveils preclinical data for novel transdermal drug delivery platform 1223
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 1 - 30 of 419

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Tau and Amyloid Beta Targeted Therapy of Alzheimer’s Disease

Order Now

Recommended Report

R&D Drug Pipeline Database
Order Now

Subscribe La Merie Biologics